Oncology Evolved

Engineering the Next Generation of Off-the-Shelf Cell Therapies

PIPELINE

PRE-CLINICAL

CLINICAL

CAR-T (Allogeneic)

T-ALL/LBL

WU-CART-007

Memory NK (Allogeneic)

AML

WU-NK-101

Solid Tumors

WU-NK-101 + mAb

Solid Tumors

WU-NK-201 Engineered

LATEST NEWS

Wugen to Present at the Upcoming Jefferies London Healthcare Conference

SAINT LOUIS, MO and SAN DIEGO, CA, November 10, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline…

Read more
Wugen to Present Data Characterizing WU-NK-101 at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

-- WU-NK-101’s differentiated memory natural killer (NK) expression profile supports enhanced anti-tumor activity and metabolic flexibility -- -- Data support…

Read more
Wugen to Present Data on WU-NK-101 for Relapsed / Refractory Acute Myelogenous Leukemia at The American Society of Hematology’s (ASH) 64th Annual Meeting

SAINT LOUIS, MO and SAN DIEGO, CA, November 3, 2022 – Wugen, Inc., a clinical-stage biotechnology company developing a pipeline…

Read more
OPTIMIZED BY EVOLUTION

Wugen is developing off-the-shelf cellular therapies for cancer

Radio Button Off
About Wugen

Wugen is a clinical-stage biotechnology company

Flask
Science

Cellular therapies originating from healthy donors

People
Careers

Come join our growing teams in San Diego and St. Louis